ATP-sensitive potassium channel Inhibitors
2 drugsAbout ATP-sensitive potassium channel
The ATP-sensitive potassium channel (KATP channel) regulates cellular excitability and metabolism. Found in pancreatic beta cells, neurons, and cardiac muscle, these channels link cellular metabolic state to electrical activity. They open or close in response to changes in intracellular ATP levels, regulating insulin secretion, neuronal firing, and vascular tone.
KATP channels are a drug target for metabolic diseases. However, there is currently no genetic evidence directly linking KATP channel mutations to specific diseases, which reduces confidence in target validation.
Two approved drugs target KATP channels: PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, and GLYBURIDE AND METFORMIN HYDROCHLORIDE. Both drugs are small molecules, with applications in metabolic disease.
Top ATP-sensitive potassium channel Drugs
HERITAGE and CHARTWELL RX are the only two companies with approved KATP channel-targeting drugs.
Low competition suggests opportunity, but also indicates potential challenges in market viability.
ATP-sensitive potassium channel Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ATP-sensitive potassium channel, using small molecule modality.
Explore novel modalities like biologics to differentiate from existing small molecule KATP channel drugs.
ATP-sensitive potassium channel Clinical Trials 1,094 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ATP-sensitive potassium channel. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 267 | 206 | 28 | 33 | 88% |
| Phase 2 | 305 | 174 | 82 | 49 | 68% |
| Phase 3 | 247 | 192 | 27 | 27 | 88% |
| Phase 4 | 275 | 203 | 41 | 31 | 83% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
ATP-sensitive potassium channel Drug Approval Timeline (2013 - 2013)
The first drug was approved in 2004, and the most recent in 2013, spanning a 10-year approval period.
The lack of recent approvals suggests market saturation or challenges in developing new KATP channel-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 489 (102 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ATP-sensitive potassium channel. A trial counts if an approved drug acting on ATP-sensitive potassium channel is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.